Serum Potassium Cutoff for Initiating Spironolactone
Initiate spironolactone only when serum potassium is <5.0 mEq/L, with an eGFR >30 mL/min/1.73 m².
Primary Recommendation
The 2022 AHA/ACC/HFSA heart failure guidelines provide the definitive threshold: spironolactone should be initiated when serum potassium is <5.0 mEq/L 1. This is a Class 1, Level A recommendation—the highest level of evidence-based guidance. The FDA labeling for spironolactone aligns with this, specifying initiation in heart failure patients with serum potassium ≤5.0 mEq/L 2.
Algorithmic Approach to Initiation
Step 1: Check baseline potassium and renal function
- Serum potassium must be <5.0 mEq/L
- eGFR must be >30 mL/min/1.73 m²
Step 2: Dose selection based on renal function
- eGFR >50 mL/min/1.73 m²: Start 25 mg daily 2
- eGFR 30-50 mL/min/1.73 m²: Consider starting 25 mg every other day due to increased hyperkalemia risk 2
Step 3: Early monitoring
- Check potassium and renal function within 1 week of initiation 1, 2
- Recheck at 4 weeks, then every 6 months 1
- More frequent monitoring needed if concurrent use of ACE inhibitors, ARBs, or other potassium-sparing agents 2
Critical Safety Thresholds After Initiation
Once therapy is started, different thresholds apply for continuation versus discontinuation:
- Potassium ≤5.5 mEq/L: Continue therapy with close monitoring 1, 3
- Potassium >5.5 mEq/L: Halve the dose and monitor closely 3
- Potassium >6.0 mEq/L: Discontinue spironolactone immediately to avoid life-threatening hyperkalemia 3 (Class 3: Harm recommendation) 1
Important Clinical Context
The <5.0 mEq/L threshold for initiation is stricter than the continuation threshold (≤5.5 mEq/L) because:
- Trial exclusion criteria: All landmark trials (RALES, EPHESUS, EMPHASIS-HF) excluded patients with potassium >5.0 mmol/L at baseline 3
- Real-world safety data: Post-RALES surveillance showed increased hyperkalemia-associated morbidity and mortality when spironolactone was prescribed outside trial parameters 3
- Additive risk: Most heart failure patients are on ACE inhibitors or ARBs, which independently increase hyperkalemia risk 2
Common Pitfalls to Avoid
Do not initiate if:
- Potassium ≥5.0 mEq/L (even 5.0 is borderline and requires caution)
- eGFR ≤30 mL/min/1.73 m² (spironolactone is partially renally excreted) 1
- Patient is on multiple potassium-sparing agents without ability to monitor closely
Do not confuse initiation with continuation thresholds:
- The 5.0 mEq/L cutoff is for starting therapy
- The 5.5 mEq/L threshold is for continuing therapy once already established 1, 3
Evidence Strength
This recommendation is supported by convergent high-quality evidence:
- Guideline consensus: Both 2022 AHA/ACC/HFSA 1 and European guidance 3 agree on the <5.0 mEq/L threshold
- FDA labeling: Official prescribing information specifies ≤5.0 mEq/L for heart failure initiation 2
- Trial data: All major efficacy trials used this cutoff as an inclusion criterion 3
The evidence is unambiguous and consistent across all authoritative sources—there is no clinical equipoise on this threshold.